ANABAnaptysBio, Inc.

$45.97+231% 1Y

Is it safe?

Mixed

Forensics clean, with a caveat: a safe balance sheet, but big price swings.

1 good, 1 to watch, 1 neutral, 3 without data
SurvivalSafe zone

Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.

Insider conviction-$249K

Insiders were net sellers (-$249K, 90 days to Oct 8, 2026), selling is often routine.

Drawdown risk79% volderived · Oct 9, 2026

Large price swings, high volatility. Worst drawdown -92% · now 34% below its 52-week high.

Unless marked, from SEC EDGAR, as of Dec 31, 2025.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Volatilitybehind 89% of the market
Max drawdownbottom 9% of the market

Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.

Can ANAB take a bad year?

The deepest fall in ANAB's price history on file is −92%; it is 34% below its high today.

2.32

Altman Z-score · distress below 1.8 · safe above 3 · grey zone: neither safe nor distressed on this model

Annualised volatility
79%

Annualised volatility · three times the market's own swing

Worst drawdown on file
−92%

Worst drawdown on file · −34% today

Details›
Cash and short-term investments
$164M
EBITDA, trailing twelve months
$313M
Operating profit, trailing twelve months
$313M
Annualised volatilitytwo years of daily moves
79%
Worst drawdown on file
−92%
Below its 52-week high
34%

Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.

On our screens:Most shorted stocks